The frequent expression of HRG in solid tumors [52], including triple-negative breast cancers, may provide an explanation as to why current FDA-approved HER TKIs have had limited clinical impact in the treatment of the majority of HER2-overexpressing and EGFR-expressing solid tumors, with the exception of head and neck cancers [53]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.